CDI In the News

September 10, 2024

MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular….

September 03, 2024

MADISON, Wisc., September 3, 2024 – FUJIFILM Cellular Dynamics and Opsis Therapeutics congratulate BlueRock Therapeutics on receiving FDA clearance of its IND application for OpCT-001, an induced pluripotent stem cell (iPSC)-derived cell therapy candidate for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance….

May 30, 2024

CAMBRIDGE, Mass., May 30, 2024 – Fujifilm Life Sciences Strategic Business Office, with a portfolio of businesses offering products, services and comprehensive solutions that span support for all stages of therapeutic development from discovery through to commercialization, announces that it will showcase its offerings at booth 5035/4835 during the BIO International Convention (June 3-6), at….

December 04, 2023

FUJIFILM to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities TOKYO, December 4, 2023 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces the investment of USD 200 million in two subsidiaries to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities. The investment will enable….

November 09, 2023

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases PHILADELPHIA and MADISON, WI, November 9, 2023 – Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, and FUJIFILM Cellular Dynamics, Inc.,….